Table 3.
Comparison of treatment of patients between the metformin group and no-metformin group
| Treatment | Metformin group (n = 104) | No-metformin group (n = 179) | P-value |
|---|---|---|---|
| Antidiabetic treatment, n (%) | |||
| Insulins | 61 (58.7%) | 91 (50.8%) | 0.20 |
| Glucosidase inhibitors | 53 (51.0%) | 80 (44.7%) | 0.31 |
| Insulin secreting drugs | 28 (26.9%) | 34 (19.0%) | 0.12 |
| Dipeptidyl peptidase-4 inhibitors | 11 (10.6%) | 16 (8.9%) | 0.65 |
| Insulin sensitizing agents | 6 (5.8%) | 6 (3.4%) | 0.33 |
| Antiviral treatment, n (%) | |||
| Arbidol | 77 (74.0%) | 125 (69.8%) | 0.45 |
| Lopinavir–ritonavir | 25 (24.0%) | 29 (16.2%) | 0.11 |
| Chloroquine/hydroxychloroquine | 8 (7.7%) | 11 (6.1%) | 0.62 |
| Ribavirin | 12 (11.5%) | 15 (8.4%) | 0.38 |
| Interferon | 10 (9.6%) | 14 (7.8%) | 0.60 |
| Chinese traditional medicine | 79 (76.0%) | 120 (67.0%) | 0.11 |
| Antibacterial treatment, n (%) | 72 (69.2%) | 124 (69.3%) | 0.99 |
| Anticoagulants, n (%) | 26 (25.0%) | 61 (34.1%) | 0.11 |
| Glucocorticoids, n (%) | 40 (38.5%) | 65 (36.3%) | 0.72 |
| Statins, n (%) | 20 (19.2%) | 35 (19.6%) | 0.95 |
Data are expressed as number (%). P-values denoted the comparison between the metformin group and no-metformin group.